Publication List

(Yusuke Masuo, Ph D.)

1) Hasan Alshammari A, Masuo Y, Fujita KI, Shimada K, Iida N, Wakayama T, Kato Y. Discrimination ofhand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity andvascular endothelial growth factor receptor-2 inhibition. Biochem Pharmacol, 197: 114914, 2022
2) Yoshihara M, Mizutani S, Matsumoto K, Kato Y, Masuo Y, Tano S, Mizutani H, Kotani T, Mizutani E,Shibata K, Kajiyama H. Crosstalk between foetal vasoactive peptide hormones and placentalaminopeptidases regulates placental blood flow: Its significance in preeclampsia. Placenta, 121: 32-39,20223) Iida N, Mizukoshi E, Yamashita T, Yutani M, Seishima J, Wang Z, Arai K, Okada H, Yamashita T, Sakai Y,Masuo Y, Agustina R, Kato Y, Fujinaga Y, Oshima M, Honda M, Lebreton F, Gilmore MS, Kaneko S.
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis. NatCancer, 2: 1039-1054, 20214) Agustina R, Masuo Y, Kido Y, Shinoda K, Ishimoto T, Kato Y. Identification of food-derived isoflavone
sulfates as inhibition markers for intestinal breast cancer resistance proteins. Drug Metab Dispos, 49: 972984, 20215) Futatsugi A, Masuo Y, Kato Y. Effects of probenecid on hepatic and renal disposition of hexadecanedioate,
an endogenous substrate of Organic anion transporting polypeptide 1b in rats. J Pharm Sci, 110: 2274-2284,20216) Masuo Y, Fujita KI, Mishiro K, Seba N, Kogi T, Okumura H, Matsumoto N, Kunishima M, Kato Y. 6Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients. Drug
Metab Pharmacokinet, 35: 555-562, 2020
7) Nishiyama M, Nakamichi N, Yoshimura T, Masuo Y, Komori T, Ishimoto T, Matsuo JI, Kato Y.
Homostachydrine is a xenobiotic substrate of OCTN1/SLC22A4 and potentially sensitizes
pentylenetetrazole-induced seizures in mice. Neurochem Res, 45: 2664-2678, 2020
8) Taguchi T, Masuo Y, Sakai Y, Kato Y. Static model-based assessment of OATP1B1-mediated druginteractions with preincubation-dependent inhibitors based on inactivation and recovery kinetics. DrugMetab Dispos, 48: 750-758, 20209) Nakamichi N, Nakao S, Nishiyama M, Takeda Y, Ishimoto T, Masuo Y, Matsumoto S, Suzuki M, Kato Y.
Oral administration of the food derived hydrophilic antioxidant ergothioneine enhances object recognition
memory in mice. Curr Mol Pharmacol, 14: 220-233, 202110) Kubota Y, Fujita KI, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Shimada K,Masuo Y, Kato Y, Sasaki Y. Higher systemic exposure to unbound active metabolites of regorafenib isassociated with short progression-free survival in colorectal cancer patients. Clin Pharmacol Ther, 108:586-595, 202011) Taguchi T, Masuo Y, Sakai Y, Kato Y. Short-lasting inhibition of hepatic uptake transporter OATP1B1 bytyrosine kinase inhibitor pazopanib. Drug Metab Pharmacokinet, 34: 372-379, 201912) Hashimoto N, Nakamichi N, Nanmo H, Kimura KI, Masuo Y, Sakai Y, Schinkel AH, Sato S, Soga T, KatoY. Metabolome analysis reveals dermal histamine accumulation in murine dermatitis provoked by genetic
deletion of P-glycoprotein and breast cancer resistance protein. Pharm Res, 36: 158, 201913) Nakamichi N, Matsumoto Y, Kawanishi T, Ishimoto T, Masuo Y, Horikawa M, Kato Y. Maturational
characterization of mouse cortical neurons three-dimensionally cultured in functional polymer FP001containing medium. Biol Pharm Bull, 42: 1545-1553, 2019114) Kawanishi T, Arakawa H, Masuo Y, Nakamichi N, Kato Y. Bile duct obstruction leads to increased
intestinal expression of breast cancer resistance protein with reduced gastrointestinal absorption of imatinib.
J Pharm Sci, 108: 3130-3137, 201915) Nakamichi N, Nakao S, Masuo Y, Koike A, Matsumura N, Nishiyama M, Al-Shammari AH, Sekiguchi H,Sutoh K, Usumi K, Kato Y. Hydrolyzed salmon milt extract enhances object recognition and location
memory through an increase in hippocampal cytidine nucleoside levels in normal mice. J Med Food, 22:408-415, 201916) Iwase M, Fujita KI, Nishimura Y, Seba N, Masuo Y, Ishida H, Kato Y, Kiuchi Y. Pazopanib interacts withirinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake,of an active metabolite SN-38. Cancer Chemother Pharmacol, 83: 993-998, 201917) Al-Shammari AH, Masuo Y, Fujita KI, Yoshikawa Y, Nakamichi N, Kubota Y, Sasaki Y, Kato Y. Influx andefflux transporters contribute to the increased dermal exposure to active metabolite of regorafenib after
repeated oral administration in mice. J Pharm Sci, 108: 2173-2179, 201918) Ishimoto T, Masuo Y, Kato Y, Nakamichi N. Ergothioneine-induced neuronal differentiation is mediatedthrough activation of S6K1 and neurotrophin 4/5-TrkB signaling in murine neural stem cells. Cell Signal,53: 269-280, 201819) Masuo Y, Ohba Y, Yamada K, Al-Shammari AH, Seba N, Nakamichi N, Ogihara T, Kunishima M, Kato Y.
Combination metabolomics approach for identifying endogenous substrates of carnitine/organic cationtransporter OCTN1. Pharm Res, 35: 224, 201820) Ellawatty WEA, Masuo Y, Fujita KI, Yamazaki E, Ishida H, Arakawa H, Nakamichi N, Abdelwahed R,Sasaki Y, Kato Y. Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase
inhibitor pazopanib. Drug Metab Dispos, 46: 33-40, 201821) Ishimoto T, Nakamichi N, Nishijima H, Masuo Y, Kato Y. Carnitine/organic cation transporter OCTN1
negatively regulates activation in murine cultured microglial cells. Neurochem Res, 43: 116-128, 201822) Takahashi S, Tanaka N, Golla S, Fukami T, Krausz KW, Polunas MA, Weig BC, Masuo Y, Xie C, Jiang C,Gonzalez FJ. Farnesoid X receptor protects against low-dose carbon tetrachloride-induced liver injury
through the taurocholate-JNK pathway. Toxicol Sci, 158: 334-346, 201723) Fujita KI, Masuo Y, Yamazaki E, Shibutani T, Kubota Y, Nakamichi N, Sasaki Y, Kato Y. Involvement ofthe transporters P-gp and BCRP in dermal distribution of the multi-kinase inhibitor regorafenib and its
active metabolites. J Pharm Sci, 106: 2632-2641, 201724) Yamamoto H, Takada T, Yamanashi Y, Ogura M, Masuo Y, Harada-Shiba M, Suzuki H. VLDL/LDL actsas a drug carrier and regulates the transport and metabolism of drugs in the body. Sci Rep, 7: 633, 201725) Masuo Y, Nagamori S, Hasegawa A, Hayashi K, Isozumi N, Nakamichi N, Kanai Y, Kato Y. Utilization ofliver microsomes to estimate hepatic intrinsic clearance of monoamine oxidase substrate drugs in humans.
Pharm Res, 34: 1233-1243, 201726) Hashimoto N, Nakamichi N, Yamazaki E, Oikawa M, Masuo Y, Schinkel AH, Kato Y. P-Glycoprotein inskin contributes to transdermal absorption of topical corticosteroids. Int J Pharm, 521: 365-373, 201627) Abouzed TK, Munesue S, Harashima A, Masuo Y, Kato Y, Kahilo KK, Yamamoto H, Yamamoto Y.
Preventive effect of salicylate and pyridoxamine on diabetic nephropathy. J Diabetes Res, 2016: 1786789,201628) Nakamichi N, Ishimoto T, Yamauchi Y, Masuo Y, Kato Y. Screening to identify multidrug resistanceassociated protein inhibitors with neuroblastoma-selective cytotoxicity. Biol Pharm Bull, 39: 16381645,2016229) Takahashi S, Fukami T, Masuo Y, Brocker CN, Xie C, Krausz KW, Wolf CR, Henderson CJ, Gonzalez FJ.
Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J LipidRes, 57: 2130-2137, 201630) Futatsugi A, Masuo Y, Kawabata S, Nakamichi N, Kato Y. L503F variant of carnitine/organic cationtransporter 1 efficiently transports metformin and other biguanides. J Pharm Pharmacol, 68: 1160-9, 201631) Taguchi T, Masuo Y, Kogi T, Nakamichi N, Kato Y. Characterization of long-lasting Oatp inhibition bytypical inhibitor cyclosporine A and in vitro-in vivo discrepancy in its drug interaction potential in rats. JPharm Sci, 105: 2231-2239, 201632) Nakamichi N, Nakayama K, Ishimoto T, Masuo Y, Wakayama T, Sekiguchi H, Sutoh K, Usumi K, Iseki S,
Kato Y. Food-derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts
antidepressant effect in mice. Brain Behav, 6: e00477, 201633) Tang Y, Masuo Y, Sakai Y, Wakayama T, Sugiura T, Harada R, Futatsugi A, Komura T, Nakamichi N,Sekiguchi H, Sutoh K, Usumi K, Iseki S, Kaneko S, Kato Y. Localization of xenobiotic transporter
OCTN1/SLC22A4 in hepatic stellate cells and its protective role in liver fibrosis. J Pharm Sci, 105: 17791789, 201634) Fujita K, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y,Kitamura M, Kunishima M, Sasaki Y, Kato Y. Increased plasma concentrations of unbound SN-38, theactive metabolite of irinotecan, in cancer patients with severe renal failure. Pharm Res, 33: 269-282, 201635) Takada T, Yamanashi Y, Konishi K, Yamamoto T, Toyoda Y, Masuo Y, Yamamoto H, Suzuki H. NPC1L1
is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy. Sci Transl Med,7: 275ra23, 201536) Shimizu T, Kijima A, Masuo Y, Ishimoto T, Sugiura T, Takahashi S, Nakamichi N, Kato Y. Gene ablationof carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminosalicylate in mice.
Chem Pharm Bull, 38: 774-780, 201537) Shimizu T, Masuo Y, Takahashi S, Nakamichi N, Kato Y. Organic cation transporter Octn1-mediated uptakeof food-derived antioxidant ergothioneine into infiltrating macrophages during intestinal inflammation inmice. Drug Metab Pharmacokinet, 30: 231-239, 201538) IshimotoT, Nakamichi N, Hosotani H, Masuo Y, Sugiura T and Kato Y. Organic cation transporter-mediatedergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation
into neurons. PLoS One, 9: e89434, 201439) Takeuchi K, Sugiura T, Matsubara K, Sato R, Shimizu T, Masuo Y, Horikawa M, Nakamichi N, Ishiwata
N, Kato Y. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer
resistance protein in human. Drug Metab Dispos, 42: 726-734, 201440) Masuo Y, Ito K, Yamamoto T, Hisaka A, Honma M, Suzuki H. Characterization of inhibitory effect ofcarbapenem antibiotics on the deconjugation of valproic acid glucuronide. Drug Metab Dispos, 38: 18281835, 20103